Free Trial

Akari Therapeutics (AKTX) Stock Forecast & Price Target

Akari Therapeutics logo
$0.92 -0.02 (-1.90%)
Closing price 10/3/2025 03:59 PM Eastern
Extended Trading
$0.91 0.00 (-0.33%)
As of 10/3/2025 06:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Akari Therapeutics - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Sell
1
Hold
0
Buy
2

Based on 3 Wall Street analysts who have issued ratings for Akari Therapeutics in the last 12 months, the stock has a consensus rating of "Hold." Out of the 3 analysts, 1 has given a sell rating, and 2 have given a buy rating for AKTX.

Consensus Price Target

$3.30
260.26% Upside
According to the 3 analysts' twelve-month price targets for Akari Therapeutics, the average price target is $3.30. The highest price target for AKTX is $5.00, while the lowest price target for AKTX is $1.60. The average price target represents a forecasted upside of 260.26% from the current price of $0.92.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for AKTX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Akari Therapeutics and its competitors.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

AKTX Analyst Ratings Over Time

TypeCurrent Forecast
10/5/24 to 10/5/25
1 Month Ago
9/5/24 to 9/5/25
3 Months Ago
7/7/24 to 7/7/25
1 Year Ago
10/6/23 to 10/5/24
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
N/A N/A
Buy
2 Buy rating(s)
1 Buy rating(s)
N/A N/A
Hold
0 Hold rating(s)
0 Hold rating(s)
N/A N/A
Sell
1 Sell rating(s)
0 Sell rating(s)
N/A N/A
Consensus Price Target$3.30$5.00N/AN/A
Forecasted Upside260.26% Upside510.72% UpsideN/AN/A
Consensus RatingHoldBuyN/AN/A

AKTX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

AKTX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Akari Therapeutics Stock vs. The Competition

TypeAkari TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
2.33
2.33
2.51
Consensus RatingHoldHoldModerate Buy
Predicted Upside260.26% Upside1,395.17% Upside10.49% Upside
News Sentiment Rating
Neutral News

See Recent AKTX News
Positive News
Positive News
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
9/27/2025Weiss Ratings
0 of 5 stars
 Reiterated RatingSell (E+)
9/9/2025HC Wainwright
1 of 5 stars
Sean Lee
Sean Lee
1 of 5 stars
Reiterated RatingBuy$1.60+88.23%
7/18/2025Maxim Group
1 of 5 stars
Jason McCarthy
Jason McCarthy
1 of 5 stars
Initiated CoverageBuy$5.00+342.47%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 03:28 PM ET.


AKTX Forecast - Frequently Asked Questions

According to the research reports of 3 Wall Street equities research analysts, the average twelve-month stock price forecast for Akari Therapeutics is $3.30, with a high forecast of $5.00 and a low forecast of $1.60.

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Akari Therapeutics in the last year. There is currently 1 sell rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" AKTX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AKTX, but not buy additional shares or sell existing shares.

According to analysts, Akari Therapeutics's stock has a predicted upside of 260.26% based on their 12-month stock forecasts.

Akari Therapeutics has been rated by research analysts at HC Wainwright, Maxim Group, and Weiss Ratings in the past 90 days.

Analysts like Akari Therapeutics more than other "medical" companies. The consensus rating score for Akari Therapeutics is 2.33 while the average consensus rating score for "medical" companies is 2.33. Learn more on how AKTX compares to other companies.


This page (NASDAQ:AKTX) was last updated on 10/5/2025 by MarketBeat.com Staff
From Our Partners